Related Experiment Video
Updated: Feb 11, 2026

Author Spotlight: Developing a Simple and Robust Hepatic Model for Pharmacological and Toxicological Applications
Published on: October 20, 2023
Take a Bow, Pharma, for the Hepatitis C Drugs
Direct-acting antivirals transformed hepatitis C treatment, offering significant patient health benefits despite high costs. This breakthrough in antiviral therapy improved outcomes for many.
Area of Science:
- Hepatology
- Virology
- Pharmacoeconomics
Background:
- Hepatitis C virus (HCV) infection poses a significant global health burden.
- Previous treatments for hepatitis C had limitations in efficacy and duration.
- The advent of direct-acting antivirals (DAAs) marked a paradigm shift in HCV management.
Purpose of the Study:
- To evaluate the impact of direct-acting antivirals on hepatitis C treatment.
- To assess the benefits and economic implications of new antiviral therapies.
- To understand the societal return on investment for advanced hepatitis C medications.
Main Methods:
- Review of clinical trial data for direct-acting antivirals.
- Analysis of hepatitis C treatment outcomes and patient recovery rates.
- Economic evaluation of DAA pricing and healthcare system impact.
Main Results:
- Direct-acting antivirals have demonstrated high cure rates for hepatitis C.
- Significant improvements in patient health and quality of life were observed.
- The introduction of DAAs led to substantially increased medication costs.
Conclusions:
- Direct-acting antivirals represent a revolutionary advancement in treating hepatitis C.
- The substantial health benefits to patients and society justify the high cost of these novel therapies.
- Future research should focus on sustainable pricing models for innovative antiviral treatments.
Related Concept Videos
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
Hepatic Drug Excretion: Influencing Factors
Hepatic Drug Clearance: Role of Transporters
Hepatic Drug Excretion: Enterohepatic Cycling
Post-release drugs and metabolites can be reabsorbed into the body from the intestine. For conjugated metabolites like glucuronides, reabsorption requires enzymatic hydrolysis by intestinal microflora. This...
Hepatic Drug Clearance: Effect of Protein Binding
For low-extraction-ratio drugs that are less than 80% protein-bound, minor changes in protein binding...
Hepatic Drug Clearance: Restrictive and Nonrestrictive Clearance
Most drugs undergo restrictive clearance, which is proportional to the...

